Azitra, Inc.
$0.21
▼
-3.1%
2026-04-21 05:32:00
azitrainc.com
ASE: AZTR
Explore Azitra, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.48 M
Current Price
$0.21
52W High / Low
$2.66 / $0.1
Stock P/E
—
Book Value
$0.35
Dividend Yield
—
ROCE
-277.12%
ROE
-2.31%
Face Value
—
EPS
$-2.25
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
13
Beta
-2.17
Debt / Equity
11.1
Current Ratio
2.83
Quick Ratio
2.83
Forward P/E
-0.44
Price / Sales
—
Enterprise Value
$2.03 M
EV / EBITDA
-0.19
EV / Revenue
—
Rating
None
Target Price
$1.35
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Cytokinetics, Incorporated | $65.05 | — | $8.11 B | — | -50.1% | 197.47% | $70.98 / $29.31 | $-5.37 |
| 2. | Pharvaris N.V. | $28.97 | — | $1.86 B | — | -54.28% | -65.19% | $29.89 / $13.6 | $5.56 |
| 3. | Cybin D/B/A Helus Pharma | $5.61 | — | $1.92 M | — | -60.35% | -55.89% | $12.7 / $5.9 | $5.49 |
| 4. | Amicus Therapeutics, Inc. | $14.46 | — | $4.54 B | — | 4.84% | -11.58% | $14.48 / $5.51 | $0.88 |
| 5. | Erasca, Inc. | $21.71 | — | $5.91 B | — | -35.74% | -33.27% | $19.78 / $1.06 | $1.14 |
| 6. | 60 Degrees Pharmaceuticals, Inc. | $1.84 | — | $4.69 M | — | -220.2% | -2.01% | $17.68 / $1.29 | $-5.25 |
| 7. | ProKidney Corp. | $2.1 | — | $634.02 M | — | -54.13% | -43.17% | $7.13 / $0.54 | $-7.13 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -2.23 M | -2.77 M | -2.87 M | -3.1 M | -2.43 M | — |
| Net Profit | -2.23 M | -2.76 M | -2.89 M | -3.07 M | -2.39 M | — |
| EPS in Rs | -0.14 | -0.17 | -0.18 | -0.19 | -0.15 | -1.14 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0.01 M | 0.69 M | 0.28 M |
| Operating Profit | -10.97 M | -10.99 M | -7.45 M | -9.45 M |
| Net Profit | -10.96 M | -8.97 M | -11.28 M | -10.68 M |
| EPS in Rs | -0.68 | -0.55 | -0.7 | -0.66 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 5.03 M | 7.36 M | 5.12 M | 7.17 M |
| Total Liabilities | 1.22 M | 1.66 M | 2.2 M | 43.43 M |
| Equity | 3.8 M | 5.7 M | 2.91 M | -36.26 M |
| Current Assets | 3.02 M | 5.23 M | 2.54 M | 4.14 M |
| Current Liabilities | 1.07 M | 1.38 M | 1.6 M | 2.22 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -11.22 M | -10.18 M | -7.36 M | -8.35 M |
| Investing CF | -0.18 M | -0.38 M | -0.32 M | -0.34 M |
| Financing CF | 8.92 M | 13.32 M | 5.98 M | 4.13 M |
| Free CF | -11.41 M | -10.56 M | -7.68 M | -8.69 M |
| Capex | -0.19 M | -0.38 M | -0.32 M | -0.34 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -98.91% | 141.55% | — | — |
| Earnings Growth % | 20.53% | -5.65% | — | — |
| Profit Margin % | -119566.56% | -1644.87% | -3760.69% | — |
| Operating Margin % | -146468.53% | -1086.09% | -3328.73% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -113307.53% | -1555.86% | -3529.05% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-08-21 | 1:0.15 |
| 2024-07-01 | 1:0.0333333 |